Additionally, data suggest that blocking EGFR can effectively increase the antitumor activity of selumetinib in triple-negative breast cancer, which may be related to the effect of this combination on the activation of extracellular signal-regulated kinase 1/2 and AKT [29]. Here, AKT1 is linked to triple-negative breast carcinoma.